Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: experience from a consecutive cohort of inflammatory bowel disease patients.

Abstract excerpt

BACKGROUND: The monoclonal anti tumor necrosis factor (TNF) antibody adalimumab has recently been approved for Crohn's disease (CD) and evaluated for ulcerative colitis (UC). Cutaneous lesions associated with its administration have not been prospectively studied in inflammatory bowel disease (IBD). METHODS: We evaluated the first 50 consecutive patients (female n = 30, median age 32½ years, interquartile range...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Adalimumab
• Share to Anti-Inflammatory Agents